May 12, 2017

Number To Know…1,000

Vigilant Biosciences has initiated a US FDA clinical study, with plans to recruit up to 1,000 patients, of its OncAlert point-of-care oral cancer risk assessment test. Source: Medtech Insight

Read

May 12, 2017

Oral Cancer Tests

The OncAlert oral cancer product line from Vigilant Biosciences Inc., Fort Lauderdale, Fla, includes the OncAlert oral cancer rapid test and the OncAlert oral cancer lab test, available in countries accepting CE mark. The tests are based on technology that accurately measures CD44, a tumor-initiating…

Read

May 12, 2017

Clinical Lab Trends for 2017

Oral cancer - including cancers of the mouth and throat - is an area that is attracting new attention from the diagnostic community - this time with the help of dentists. New, promising technologies are making it easier for dental and medical professionals to detect…

Read

May 12, 2017

Vigilant Biosciences Launches Clinical Studies of Oral Cancer Assay

Vigilant Biosciences has launched patient enrollment for clinical studies of its OncAlert point-of-care qualitative assay in support of its registration submission to the Food and Drug Administration (FDA). The clinical studies are designed to validate the performance and evaluate the implementation of the OncAlert RAPID…

Read

May 5, 2017

The Word of Mouth on Oral Cancer

Nearly 50,000 people are diagnosed with oral cancer in the U.S. each year—and that number continues to grow, particularly among certain segments of the population. While all adults should be screened for oral cancer annually, those who smoke or use smokeless tobacco, and/or consume alcohol…

Read